Assessing the Effectiveness of a Grand Rounds CME Activity for Health-care Professionals

Overview

Journal J Cancer Educ

Publisher Springer

Specialties Medical Education
Oncology

Date 2013 Jun 27

PMID 23801053

Authors

Terry Ann Glauser

P Holder Nevins

J Chad Williamson

Brian Tomlinson

Affiliations

Soon will be listed here.

Abstract

The Lymphoma Research Foundation offers Grand Rounds continuing medical education (CME) activities on specific issues related to advances in the management of patients with lymphoma. The 2012 activity comprised interactive case studies presented by local lymphoma experts. A case-based survey was designed to assess whether the management choices of program participants are consistent with the evidence-based content of the CME activity. This survey was administered to participants 1 month after completion of the CME activity and also to a control group who did not participate in the educational program. Participants were more aware of the epidemiology of CD20-positive tumors than were controls and were more likely to appropriately diagnose primary mediastinal large B cell lymphoma (PMBCL), use evidence-based second-line therapy for PMBCL, and properly manage a patient with classic Hodgkin lymphoma that did not respond to standard therapy. Participants were also more confident than controls in their ability to interpret histology and cytogenetic testing for selecting an optimal treatment.

References

Moskowitz C, Bertino J, Glassman J, Hedrick E, Hunte S, Agus D . Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol. 1999; 17(12):3776-85. DOI: 10.1200/JCO.1999.17.12.3776. View

Gatcliffe T, Coleman R . Tumor board: more than treatment planning--a 1-year prospective survey. J Cancer Educ. 2008; 23(4):235-7. DOI: 10.1080/08858190802189014. View

Steidl C, Gascoyne R . The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood. 2011; 118(10):2659-69. DOI: 10.1182/blood-2011-05-326538. View

Siegel R, Naishadham D, Jemal A . Cancer statistics, 2012. CA Cancer J Clin. 2012; 62(1):10-29. DOI: 10.3322/caac.20138. View

Dimopoulos M, Gertz M, Kastritis E, Garcia-Sanz R, Kimby E, Leblond V . Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol. 2008; 27(1):120-6. DOI: 10.1200/JCO.2008.17.7865. View

Smith A, Law C, Khalifa M, Hsieh E, Hanna S, Wright F . Multimodal CME for surgeons and pathologists improves colon cancer staging. J Cancer Educ. 2003; 18(2):81-6. DOI: 10.1207/S15430154JCE1802_09. View

Sparano J, Wiernik P, Leaf A, Dutcher J . Infusional cyclophosphamide, doxorubicin, and etoposide in relapsed and resistant non-Hodgkin's lymphoma: evidence for a schedule-dependent effect favoring infusional administration of chemotherapy. J Clin Oncol. 1993; 11(6):1071-9. DOI: 10.1200/JCO.1993.11.6.1071. View

Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D . Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003; 348(24):2386-95. DOI: 10.1056/NEJMoa022473. View

Petty J, Vetto J . Beyond doughnuts: tumor board recommendations influence patient care. J Cancer Educ. 2002; 17(2):97-100. DOI: 10.1080/08858190209528807. View

10.

Mantovani A . B cells and macrophages in cancer: yin and yang. Nat Med. 2011; 17(3):285-6. DOI: 10.1038/nm0311-285. View

11.

Davis D, Thomson M, Oxman A, Haynes R . Changing physician performance. A systematic review of the effect of continuing medical education strategies. JAMA. 1995; 274(9):700-5. DOI: 10.1001/jama.274.9.700. View

12.

Watson E, Clements A, Yudkin P, Rose P, Bukach C, Mackay J . Evaluation of the impact of two educational interventions on GP management of familial breast/ovarian cancer cases: a cluster randomised controlled trial. Br J Gen Pract. 2001; 51(471):817-21. PMC: 1314127. View

13.

Velasquez W, McLaughlin P, Tucker S, Hagemeister F, SWAN F, Rodriguez M . ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol. 1994; 12(6):1169-76. DOI: 10.1200/JCO.1994.12.6.1169. View

14.

Gallamini A, Patti C, Viviani S, Rossi A, Fiore F, Di Raimondo F . Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. Br J Haematol. 2010; 152(5):551-60. DOI: 10.1111/j.1365-2141.2010.08485.x. View

15.

Cheson B, Pfistner B, Juweid M, Gascoyne R, Specht L, Horning S . Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25(5):579-86. DOI: 10.1200/JCO.2006.09.2403. View

16.

Vassilakopoulos T, Pangalis G, Katsigiannis A, Papageorgiou S, Constantinou N, Terpos E . Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care. Oncologist. 2012; 17(2):239-49. PMC: 3286173. DOI: 10.1634/theoncologist.2011-0275. View

17.

Leong C, Shakespeare T, Mukherjee R, Back M, Lee K, Lu J . Efficacy of an integrated continuing medical education (CME) and quality improvement (QI) program on radiation oncologist (RO) clinical practice. Int J Radiat Oncol Biol Phys. 2006; 66(5):1457-60. DOI: 10.1016/j.ijrobp.2006.07.018. View

18.

Braithwaite D, Emery J, de Lusignan S, Sutton S . Using the Internet to conduct surveys of health professionals: a valid alternative?. Fam Pract. 2003; 20(5):545-51. DOI: 10.1093/fampra/cmg509. View

19.

Schmitz N, Pfistner B, Sextro M, Sieber M, Carella A, Haenel M . Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet. 2002; 359(9323):2065-71. DOI: 10.1016/S0140-6736(02)08938-9. View

20.

Velasquez W, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S . Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 1988; 71(1):117-22. View